Comparison · NCT02358343-ebf78c52
Engagement Interview vs Control Visit: Number of Participants Who Initiated Depression Treatment
Calculated by ConductScience from the counts the trial posted to ClinicalTrials.gov.
2 sourcestrial-comparisons-2026-03-23-0.1.0
Download JSON
Cite this record
ConductScience Library. Engagement Interview vs Control Visit: Number of Participants Who Initiated Depression Treatment. Trial comparisons, record NCT02358343-ebf78c52. Release trial-comparisons-2026-03-23-0.1.0, 23 Mar 2026. https://conductscience.org/library/comparisons/NCT02358343-ebf78c52
On this page
Measures6
Calculated by ConductScience from the counts the trial posted to ClinicalTrials.gov.
| Measure | Value | 95% interval, lower | 95% interval, upper | Method | Note |
|---|---|---|---|---|---|
| Risk in group 1 | 0.663 | 0.558 | 0.754 | wilson | |
| Risk in group 2 | 0.643 | 0.536 | 0.737 | wilson | |
| Risk difference, group 1 minus group 2 | 0.0199 | -0.121 | 0.16 | newcombe hybrid score | |
| Risk ratio, group 1 over group 2 | 1.03 | 0.828 | 1.28 | log | |
| Odds ratio, group 1 over group 2 | 1.09 | 0.581 | 2.05 | log | |
| Number needed to treat, for one more participant with the outcome on Engagement Interview than on Control Visit | 50.2 | from the risk difference interval | the interval includes no difference |
Source ClinicalTrials.gov
Groups2
Group 2 names the comparator: control.
| Group | Title | Description | With the outcome | Analysed | ClinicalTrials.gov code |
|---|---|---|---|---|---|
| Group 1 | Engagement Interview | Subjects will be randomly assigned to engagement interview or a control visit.Trained CBT therapists at each of the three sites will conduct the engagement interview. The session will be aimed at improving the acceptance of the diagnosis of depression by patients and treatment for the same.~Engagement Interview: An Engagement Interview will comprise a one-on-one session with the patient, during which the health-care provider will use reflective statements and non-judgmental listening techniques, will explore barriers to treatment, and will help patient articulate ambivalence about engaging in treatment. This session will be enhanced with a 40-minute DVD that the subject will watch with the therapist in the dialysis facility. The subject will be encouraged to take the DVD home with them and watch it with their family members as well. | 57 | 86 | OG000 |
| Group 2 | Control Visit | Subjects will be randomly assigned to engagement interview or a control visit. Individuals assigned to control visit will be scheduled for a follow-up discussion with a member of the research team. During this session, they will be informed of the diagnosis of major depression or dysthymia, the options for treatment available through the clinical trial, and alternatives should they decline participation in the clinical trial. | 54 | 84 | OG001 |
Source ClinicalTrials.gov
Outcome
- Type
- PRIMARY
- Title
- Number of Participants Who Initiated Depression Treatment
- Description
The primary measure of efficacy of the Engagement Interview will be the number of patients undergoing hemodialysis with co-morbid depression who initiate treatment for the condition.~This will be defined as one of the following:~* Completing at least one psychotherapy session either as a part of the clinical trial or in the community within four weeks of establishing a diagnosis of major depression and/or dysthymia.~* Receiving a supply of anti-depressant drug either as a part of the clinical trial or the treating physician within four weeks of establishing a diagnosis of major depression and/or dysthymia.
- Time frame
- within four weeks of engagement interview or control visit
- Population
Source ClinicalTrials.gov
Trial
- Title
- A Trial of Sertraline vs. CBT for End-stage Renal Disease Patients With Depression {ASCEND}
- NCT number
- NCT02358343
- Phases
- PHASE3
- Conditions
- Depression, End Stage Renal Disease
- Interventions
- Engagement Interview, Cognitive Behavioral Therapy, Antidepressant Drug Therapy
- Lead sponsor
- University of Washington
- Results first posted
- 2019-07-23
- Results on ClinicalTrials.gov
- https://clinicaltrials.gov/study/NCT02358343?tab=results
Source ClinicalTrials.gov
Source
- Release
- trial-comparisons-2026-03-23-0.1.0
- Release manifest SHA-256
- f66225897fbf258b57ea10bdacfd0347d3cdfda93f7f5685234b7e06ea36fa57
- AACT copy
- 2026-03-23
- Tables read
- outcome_counts.parquet, outcome_measurements.parquet, outcomes.parquet, reported_event_totals.parquet, reported_events.parquet, result_groups.parquet, studies.parquet, ctgov_trial.parquet
Source ClinicalTrials.gov
Sources 2
- ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
- ClinicalTrials.govNo license stated
Each source's terms
- ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
- ClinicalTrials.govnone stated
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions. The measures are ConductScience's calculation from them.
For software
Read this comparison from software.
The record is JSON. No key.
GET https://conductscience.org/api/comparisons/v1/NCT02358343-ebf78c52